INTRODUCTION
Between January 1997 and December 2000 five review articles were published examining the issue of administering recombinant erythropoietin (rEpo) to very low birth weight (VLBW; <1500 g) neonates to diminish erythrocyte transfusions. 1 -5 However, none of the reviews used the technique of meta-analysis to produce summary statistics of the published literature. Furthermore, each review examined a wide variety of studies, regardless of their individual design. Recently, Vamvakas and Strauss employed a meta-analysis approach to examine 21 studies published from 1990 to 1999. 6 They concluded that a benefit of rEpo in reducing transfusions was detected across high-quality studies using conservative erythrocyte transfusions criteria. 6 However, they noted significant heterogeneity in the results of the various studies.
We judged that some of this heterogeneity in study results is the result of variation in the time at which the rEpo treatment was begun, and that some heterogeneity is the result of variations in study design. The present meta-analysis was undertaken in an attempt to reduce these sources of heterogeneity, and to perhaps thereby come to more confident conclusions regarding rEpo treatment of VLBW infants. Specifically, we performed an aggregate analysis of only those studies that began the rEpo or placebo treatment after the first week of life, and we included only those studies that used a placebocontrolled, randomized design. Using the studies that met these criteria, we assessed the effect of the dose of rEpo on the number of transfusions received, and we calculated summary statistics to describe the odds ratios (ORs) and 95% confidence intervals (CIs) for receiving transfusions.
MATERIALS AND METHODS Study Identification and Assessment
The guidelines set forth by the Cochrane Neonatal Review Group 7 were used to identify relevant studies. The search was initiated by reviewing personal files. The identified studies and all subsequently retrieved articles were scanned for additional references. In addition, Medline was searched from January 1990 to December 2000 using the following search terms: erythropoietin, rEpo, Epo, neonate, infant, newborn. No language restrictions were applied. The inclusion criteria for entry on the study were: (1) a randomized, placebocontrolled, and double-masked design and (2) the rEpo or placebo treatment was started after the first week of life to newborn infants with birth weights 1500 g. Eight studies were deemed acceptable for inclusion in the analysis. The outcome measures were the proportion of patients receiving erythrocyte transfusions and the number of transfusions per patient, focusing exclusively on the erythrocyte transfusions that were given after the third week (day 22)
OBJECTIVES:
Using the approach of a meta -analysis, we sought to determine whether the administration of recombinant erythropoietin ( rEpo ) to very low birth weight ( VLBW ) infants, after the first week of life, results in fewer ''late'' transfusions.
STUDY DESIGN AND METHODS:
The guidelines set forth by the Cochrane Neonatal Review Group were used to identify all relevant studies. Medline was searched from January 1990 to November of 2000. Studies that used a randomized, placebo -controlled, and double -masked design were deemed acceptable.
RESULTS:
Eight studies meet the inclusion criteria. These involved 357 VLBW neonates: 183 rEpo and 174 placebo recipients. The neonates in the rEpo group received fewer erythrocyte transfusions during the study period than did those in the placebo group; the common odds ratio ( OR ) = 0.33; 95% confidence interval ( CI ) 0.21 -0.51. Furthermore, the rEpo effect size was a function of the dose of rEpo administered ( p = 0.0001 ).
CONCLUSION:
A meta -analysis of the most scientifically rigorous studies on this topic indicates that administration of rEpo to VLBW infants reduces ''late'' erythrocyte transfusions in a dose -dependent manner.
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of life and before hospital discharge. The studies that were deemed acceptable for inclusion in the meta-analysis were independently reviewed (M.G.G. and R.D.C.) in a nonblinded fashion.
Statistical Considerations
For the outcome ''proportion of patients receiving transfusions,'' we were able to ascertain the individual count data from the literature from all eight studies. For the outcome ''number of transfusions per patient,'' we had aggregate data summarized by means for six studies.
Three primary covariates were examined, rEpo dose, birth weight, and whether the publication stated that transfusion guidelines were in place at the time of the study. The rEpo dose was standardized as the cumulative rEpo U/kg per week. Birth weight was adjusted for, in the model, using the average birth weight per treatment arm.
The proportion of subjects receiving at least one transfusion was fit using a standard logistic regression model with the three covariates described above. A dose-response curve, modeling the probability of a transfusion as a function of cumulative weekly rEpo dose, was generated from this model, along with the corresponding 95% confidence band. Because the probability of transfusion appeared to be a function of the rEpo dose administered, we devised a measure of the number of transfusions expected for every 10 rEpo-treated patients at doses 0, 500, 1000 and 1500 U/kg per week. This is given by multiplying 10 times the logistic regression function. The average number of patients receiving transfusions was regressed on the three covariates listed above using weighted least squares. The weights were set to be inversely proportional to the standard deviations for each rEpo dose by study group. In addition, we generated summary weighted averages and standard deviations per rEpo dose along with the corresponding 95% CIs. For each individual study, the OR and corresponding exact 95% CIs were calculated for the odds of at least one transfusion for rEpo relative to placebo.
RESULTS
Eight studies met the inclusion criteria. 8 -15 Features of these studies, including age at the entry to the study, the rEpo-dosing schedule, number of transfusions given during the study period, and number of transfused versus not-transfused patients, are summarized in Table 1 . The studies are listed according to chronological order of publication. Dosing of rEpo ranged from a low of 100 U/kg per week (study 3) 10 to 1400 U/kg per week (study 4). 11 One study used intravenous administration (study 1) 8 and the other seven used subcutaneous administration. 9 -15 All eight studies used enteral iron at doses ranging from 2 to 6 mg/ kg per day. All the studies indicated that they had transfusion guidelines instituted at the beginning of the study.
The eight studies involved an aggregate of 357 VLBW infants: 183 rEpo and 174 placebo recipients. The probability of receiving any erythrocyte transfusion (whether one or multiple) was a function of the rEpo dose (p=0.0001), as seen by the dose-response curve ( Figure 1 ). Birth weight and having erythrocyte transfusion guidelines in place were not significant factors.
The ''number needed to treat'' assessment was made by calculating the number of transfusions given for every 10 neonates treated with rEpo. This was also found to be a function of the dose of rEpo used. Based on the logistic regression function, with parameters 0 =0.61 and 1 = À0.0022, we calculated the following: For every 10 patients treated with placebo, 6.5 would be expected to receive a ''late'' transfusion; for every 10 treated with rEpo at a dose of 500 U/kg per week, 3.8 would receive a transfusion; for every 10 treated at 1000 U/ kg per week, 1.7 would receive a transfusion; and for every 10 treated at 1500 U/kg per week, 0.6 would receive a transfusion. Similarly, from the weighted regression analysis we found that the average number of transfusions per patient was a function of the rEpo dose given (p=0.01), and that birth weight and having transfusions guidelines in place were not significant 
DISCUSSION
Patients currently in a neonatal intensive care unit (NICU) receive fewer erythrocyte transfusions than did NICU patients 15 years ago. 16 Some of this reduction is secondary to establishment of transfusion guidelines, 17 and some is due to a concerted effort to obtain less blood for laboratory testing. 18 Whether the administration of rEpo can further reduce transfusions in the NICU is still somewhat controversial, even after a decade of study. 1 -6 Erythrocyte transfusions in the NICU are sometimes categorized as ''early'' if given during the first 3 weeks of life, and as ''late'' if given thereafter. 1 -3 The relatively large phlebotomy volumes that can be required to manage ill VLBW patients often necessitate ''early'' transfusions. In contrast, ''late'' transfusions are more often given because of a peculiar hyporegenerative anemia termed the ''anemia of prematurity,'' in which circulating Epo concentrations are lower than anticipated based on the low hematocrit. 19 In a previous report we utilized meta-analysis techniques to determine whether administering rEpo, beginning in the first days of life, would prevent ''early'' transfusions. 20 Using the discontinuous variable, ''transfusion received: yes versus no,'' we found only four statistically informative studies. Summary statistics of those four showed that rEpo treatment reduced the odds of receiving an ''early'' transfusion, OR=0.59 (95% CI, 0.36-0.97; p=0.0365). On that basis, we judged that the ''early'' administration of rEpo to VLBW neonates moderately reduces (41% reduction) the proportion that will receive erythrocyte transfusions during the first 3 weeks of life.
The present study focused on whether rEpo prevents ''late'' transfusions in the NICU. To accomplish this we performed a meta-analysis summarizing the most scientifically rigorous reports that have been published addressing this issue. Eight studies, which individually included 8 to 157 patients, with 357 in the aggregate, were systematically evaluated. In the pooled analysis, the rEpo recipients were given significantly fewer transfusions than the placebo recipients were. In considering the eight studies, and generating summaries of their findings, differences between the studies as well as similarities were considered. For instance, supplemental iron was provided in all eight studies, but the dosing differed. In the first Shannon et al. study, 3 mg/kg per day was provided orally. 8 Kumar et al. used 6 mg/kg per day orally for the entire study. 15 The second Shannon et al. study used 3 mg/kg per day enterally, increasing to 6 mg/ kg per day when the patients reached full caloric intake. 9 Emmerson et al., Meyer et al., Samanci et al., and the third Shannon et al. study used oral iron in doses ranging from 2 to 3 mg/kg per day. 10,12 -14 Six of the eight studies quantified phlebotomy losses. These ranged from 8.8 to 95 ml/kg and appeared to correspond inversely with birth weight. As described by Pollak et al., both the route of iron (enteral vs. parenteral) and the dose of iron are likely to affect the efficacy of rEpo treatment in NICU patients. 21 A closely related issue is the number of blood donors to which neonates are exposed. Prolonged blood storage methods have diminished donor exposures, because blood from a single donor can sometimes suffice for the entire transfusion needs of an individual neonate. 22 Nevertheless, each transfusion, even if from the same donor, carries known and unknown risks, and has associated costs, and it can be argued that decreasing the number of transfusions, not just donor exposures, is a worthwhile goal. In the present analysis, the number of blood donors to which neonates were exposed could not be determined.
From the present analysis, we conclude that administering rEpo to VLBW neonates can result in a modest reduction in ''late'' erythrocyte transfusions, and that this effect is dependent on the dose of rEpo used. If reducing erythrocyte transfusions in the NICU is a desirable goal, many steps can facilitate its achievement. These include implementing transfusion criteria, 16 minimizing phlebotomy losses, 18 and administering rEpo to patients who are likely to require ''late'' transfusions. As a consistent approach to reducing ''late'' transfusions in the NICU, we recently published the following guideline: ''If a neonate is likely to need a transfusion several days hence (because of the anemia of prematurity), we begin administration of rEpo 400 U/ kg three times per week subcutaneously for 2 weeks''. 23 We maintain that this approach is consistent with the findings of this meta-analysis. 
Garcia et al.
Effect of rEpo on ''Late'' Transfusions in the NICU
